Head and Neck Cancer Clinical Trial
Official title:
A Phase I Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck
NCT number | NCT02112344 |
Other study ID # | CCR 2823 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2007 |
Est. completion date | October 2015 |
Verified date | September 2020 |
Source | Royal Marsden NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Squamous cell carcinoma of unknown primary (SCCUP) site metastatic to cervical lymph nodes at
presentation is a relatively rare entity forming about 2% of all head and neck carcinomas.
Typically patients are treated with ipsilateral modified radical neck dissection (MRND) and
post-operative radiotherapy (PORT) or chemoradiotherapy.
There is a lack of consensus on the radiotherapy target volumes that should be treated after
neck dissection. The most common radiotherapy techniques are either unilateral cervical lymph
node irradiation to achieve local control in the ipsilateral neck or TMI of the head and neck
region with the aim of eradicating the primary and the microscopic neck disease.
Treatment of the ipsilateral hemi-neck alone is of low toxicity and may achieve local control
in the cervical nodes. Potential occult primary sites in the head and neck mucosa, and any
sub-clinical metastatic disease in the contralateral side of the neck are left untreated. If
a primary tumour subsequently becomes apparent the previous radiotherapy may make further
radiotherapy difficult to deliver.
Some groups recommend bilateral neck and total mucosal irradiation in this setting claiming
improved local control. With conventional radiotherapy technique this is at the price of
significant acute toxicity and chronic morbidity, mainly xerostomia with its associated
complications and effects on quality of life (QOL).
Intensity modulated radiotherapy (IMRT) has been shown to reduce the dose to salivary gland
tissue and consequently may reduce the incidence of xerostomia and improve quality of life
(QOL) in head and neck cancer patients.
An analysis of parotid-sparing IMRT at the University of Michigan established a mean dose
threshold for both stimulated (26 Gy), and unstimulated (24 Gy) saliva flow rates. For the
same end-point (less than 25% of flow at baseline one year post radiation) Roesink et al
established a TD50 of 39 Gy.
The investigators performed a planning study to assess the feasibility of IMRT to spare the
parotid gland while delivering bilateral neck and TMI. The mean dose to the contralateral
parotid gland using IMRT was below the threshold of 24 Gy for unstimulated salivary flow,
predicting a fairly low risk of radiation induced xerostomia. The mean dose to the
ipsilateral parotid gland was 32 Gy which was below the TD50 dose based on the Roesink data.
This study assesses the safety and tolerability of delivering IMRT in clinical practice to
treat patients with SCCUP of the head and neck region, who require bilateral neck and
pan-mucosal irradiation.
Status | Completed |
Enrollment | 19 |
Est. completion date | October 2015 |
Est. primary completion date | September 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Squamous cell carcinomas metastatic to cervical lymph node with occult primary requiring bilateral neck and pan mucosal irradiation. 2. Radiotherapy either as primary therapy or post-operative (adjuvant irradiation). 3. Neoadjuvant and concomitant chemotherapy are permitted. 4. All patients must be suitable to attend regular follow-up and undergo toxicity assessment. 5. Stage T0, N1-3, M0 disease 6. WHO Performance Status 0-1. 7. Patient should have a negative PET/CT scan for a primary tumour. Exclusion Criteria: 1. Previous radiotherapy to the head and neck region 2. Previous malignancy except non-melanoma skin cancer 3. Previous or concurrent illness which in the investigators opinion would interfere with either completion of therapy or follow-up 4. Prophylactic use of amifostine or pilocarpine is not allowed 5. Brachytherapy is not allowed as part of the treatment |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Royal Marsden NHS Foundation Trust |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of delivering IMRT | Feasibility of delivering IMRT in this setting i.e. all the patients completing the radiotherapy protocol without treatment breaks due to toxicity. | 7 weeks after starting radiotherapy | |
Secondary | Incidence of acute dermatitis | Outcome measured at baseline, weeks 1-6 during RT. Weeks 1-4 and 8 after RT. | 3 months after RT | |
Secondary | Incidence of >grade 1 late xerostomia | Outcome measured at 3, 6, 12, 18, 24 months after RT. | 5 years | |
Secondary | Number of patients who do not relapse at the local site | Local control assessed at 3, 6 months, then every 6 months to 5 years. | 5 years | |
Secondary | Overall survival | Assessed at 3 and 6 months then every 6 months to 5 years. | 5 years | |
Secondary | Incidence of acute alopecia | Outcome measured at baseline, weeks 1-6 during RT. Weeks 1-4 and 8 after RT. | 3 months after RT | |
Secondary | Incidence of >grade 1 acute dysphagia | Outcome measured at baseline, weeks 1-6 during RT. Weeks 1-4 and 8 after RT. | 3 months after RT | |
Secondary | Incidence of > grade 1 acute mucositis | Outcome measured at baseline, weeks 1-6 during RT. Weeks 1-4 and 8 after RT. | 3 months after RT | |
Secondary | Incidence of acute radiation induced pain | Outcome measured at baseline, weeks 1-6 during RT. Weeks 1-4 and 8 after RT. | 3 months after RT | |
Secondary | Incidence of >grade 1 acute xerostomia | Outcome measured at baseline, weeks 1-6 during RT. Weeks 1-4 and 8 after RT. | 3 months after RT | |
Secondary | Incidence of acute radiation induced fatigue | Outcome measured at baseline, weeks 1-6 during RT. Weeks 1-4 and 8 after RT. | 3 months after RT | |
Secondary | Incidence of > grade 1 late dysphagia | Outcome measured at 3, 6, 12, 18, 24 months after RT. | 5 years after RT | |
Secondary | Incidence of late oesophageal stricture | Outcome measured at 3, 6, 12, 18, 24 months after RT. | 5 years after RT | |
Secondary | Incidence of >grade 1 late hoarse voice | Outcome measured at 3, 6, 12, 18, 24 months after RT. | 5 years after RT | |
Secondary | Incidence of late radiation induced neurological dysfunction | Outcome measured at 3, 6, 12, 18, 24 months after RT. | 5 years | |
Secondary | Incidence of >grade1 late skin toxicity | Outcome measured at 3, 6, 12, 18, 24 months after RT. | 5 years after RT |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |